UroGen Pharma
URGN
89 hedge funds and large institutions have $277M invested in UroGen Pharma in 2021 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 22 increasing their positions, 36 reducing their positions, and 2 closing their positions.
450% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 2
31% more call options, than puts
Call options by funds: $2.17M | Put options by funds: $1.65M
10% more funds holding
Funds holding: 81 → 89 (+8)
6% more capital invested
Capital invested by funds: $261M → $277M (+$15.7M)
1.66% less ownership
Funds ownership: 65.87% → 64.21% (-1.7%)
39% less repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 36
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ZCA
Zeke Capital Advisors
Berwyn,
Pennsylvania
|
+$11M |
| 2 |
HCM
Horton Capital Management
Philadelphia,
Pennsylvania
|
+$4.86M |
| 3 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$4.63M |
| 4 |
RHJA
Rice Hall James & Associates
San Diego,
California
|
+$3.92M |
| 5 |
BlackRock
New York
|
+$3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WCM
Wildcat Capital Management
New York
|
-$15.3M |
| 2 |
PF
Phoenix Financial
Givatayim,
Israel
|
-$4.27M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$3.95M |
| 4 |
VOYA Investment Management
Atlanta,
Georgia
|
-$3.85M |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
-$2.02M |
URGN Hedge Fund Activity: Q1 2021 in Review
89 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in UroGen Pharma (URGN) for Q1 2021, worth a combined $277M — up 6% from $261M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new URGN positions and 2 closed out — a net gain of 9 holders — while 22 added to existing stakes and 36 trimmed.
The largest buyer was Zeke Capital Advisors, opening a new position worth an estimated $11M. The largest seller was Wildcat Capital Management, cutting an estimated $15.3M.
- 89 institutional investors held UroGen Pharma (URGN) as of Q1 2021, up from 81 in Q4 2020.
- Funds reported $277M of UroGen Pharma stock for Q1 2021, up 6% quarter-over-quarter.
- 11 funds opened new UroGen Pharma positions in Q1 2021 and 2 closed out, a net change of +9 holders.
- The largest UroGen Pharma buyer in Q1 2021 was Zeke Capital Advisors, an estimated $11M added.
- The largest UroGen Pharma seller in Q1 2021 was Wildcat Capital Management, an estimated $15.3M sold.
Based on aggregated 13F filings for Q1 2021.